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Abstract: In this paper, we compared the transfection efficiency and cytotoxicity of methylglycol-
chitosan (MG-CS) and diethylaminoethyl-chitosan (DEAE-CSI and DEAE-CSII with degrees of
substitution of 1.2 and 0.57, respectively) to that of Lipofectamine (used as a reference transfection
vector). MG-CS contains quaternary amines to improve DNA binding, whereas the DEAE-CS
exhibits pH buffering capability that would ostensibly enhance transfection efficiency by promoting
endosomal escape. Gel retardation assays showed that both DEAE-CS and MG-CS bound to
DNA at a polysaccharide:DNA mass ratio of 2:1. In Calu-3 cells, the DNA transfection activity
was significantly better with MG-CS than with DEAE-CS, and the efficiency improved with
increasing polysaccharide:DNA ratios. By contrast, the efficiency of DEAE-CSI and DEAE-CSII
was independent of the polysaccharide:DNA ratio. Conversely, in the transfection-recalcitrant
JAWSII cells, both Lipofectamine and MG-CS showed significantly lower DNA transfection activity
than in Calu-3 cells, whereas the efficiency of DEAE-CSI and DEAE-CSII was similar in both cell
lines. The toxicity of DEAE-CS increased with increasing concentrations of the polymer and its
degree of substitution, whereas MG-CS demonstrated negligible cytotoxicity, even at the highest
concentration studied. Overall, MG-CS proved to be a more efficient and less toxic transfection agent
when compared to DEAE-CS.
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1. Introduction
Gene therapy has attracted substantial attention due to its vast therapeutic potential
for the treatment of various diseases, including genetic disorders, cancer, and infections [1].
Another application of gene therapy is the use of DNA as a vaccine to induce immunity against
infectious diseases and cancers. However, despite the promising prospects of gene therapy, the lack
of highly efficient and safe gene carriers represents a major barrier to its clinical translation [2–5].
The design and development of effective and nontoxic gene delivery vectors are therefore priorities in
gene therapy.
Gene delivery systems can be broadly divided into two categories: recombinant virus
vectors and synthetic vectors. Viral vectors have shown good transduction efficiency in in vivo
experiments, but their use in clinical practice is severely limited because of their serious side effects
(e.g., immunogenicity, carcinogenicity, etc.) and the difficulties associated with vector modification [6].
These limitations have prompted the development of non-viral gene carriers, which typically consist of
different synthetic cationic polymers, including poly(ethylene)imine, poly(L-lysine)-grafted-imidazole,
and poly(β-amino)esters. However, these polymers are also limited in their application due to their
pronounced cytotoxicity [5,7].
By contrast, natural polymers, like chitosan, demonstrate transfection efficiency comparable
to that achieved with synthetic cationic polymers, but they show low toxicity and good in vivo
biosafety profiles [8–10]. Chitosan is a popular choice for gene transfer studies because of its low cost,
excellent biocompatibility, and notable biodegradability. Moreover, the abundance of primary amines
and hydroxyl groups in the chitosan backbone favors tunable chemical modification of the polymer to
enhance its efficacy for gene delivery [11,12].
The transfer of an exogenous gene to the cell nucleus requires that a series of extracellular and
intracellular obstacles first be overcome. Viruses have evolved functions to address each of these
obstacles, but synthetic vectors usually lack the necessary mechanisms. The key design criteria for
non-viral vectors must allow for: (i) condensation and protection of DNA; (ii) cellular internalization;
(iii) endosomal escape; (iv) transport through the cytoplasm; and (v) nuclear localization [13,14].
Of these steps in the gene delivery process, transport through the cytoplasm and nuclear localization
are the most inadequately investigated, and the weak characterization of the underlying mechanisms
impedes the design of improved polymeric vectors. By contrast, DNA condensation, cellular
internalization and endosomal escape have been relatively well investigated in polymeric gene delivery
vectors [5,15].
Gene delivery vectors bind to and condense DNA into small compact structures through
electrostatic interactions between the positive charges displayed on the vector backbone and the
negative phosphates along the DNA chain. The process of DNA condensation is entropically driven,
so a cationic polymer and DNA spontaneously form polyplexes upon mixing [16]. These polyplexes
protect DNA by sterically blocking the access of nucleases [17].
Once DNA is bound and condensed, the next obstacle that the delivery vector must overcome is
cellular internalization. Efficient cellular uptake requires careful optimization of various parameters
that affect cell-surface binding. These can range from the balance between specific targeting
interactions and nonspecific electrostatic binding to the cell surface and the narrow window of the
polymer:DNA ratio to the optimal ligand valency due to saturation of both receptor binding and the
cell’s internalization machinery [18]. Following successful cellular uptake, however, the polyplexes
may become entrapped in the endosomes.
One effective strategy for overcoming the endosomal barrier is the use of the proton-sponge
polymers that contain a large number of secondary and tertiary amines with pKa values that
lie in a range between the lysosomal and physiological pH (i.e., pH 4.5–7.2). In the low-pH
endosomal environment, the proton-sponge polymers undergo acidification and become protonated,
which triggers an influx of more protons into the endosomes to restore the pH. This accumulation
of protons in the vesicle must be balanced by an influx of counter ions, which, in turn, ultimately
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causes osmotic swelling and destabilization of the endosomal membrane [19], thereby facilitating the
endosomal escape of material trapped within the endosome.
In the current study, we compared the efficacy of DNA vectors fabricated from
methylglycol-chitosan (MG-CS) and diethylaminoethyl-chitosan (DEAE-CS). MG-CS is a commercially
available, water-soluble, cationic polymer that bears quaternized [–NMe3]+ and O(C2H4O)nH groups
at the C-2 and C-6 atoms, respectively, of the pyranose ring. The MG-CS derivative can efficiently
bind DNA to form self-assembling polyplexes via electrostatic interactions. However, the study of this
chitosan derivative as a gene carrier has never been reported. The second water-soluble, but uncharged,
chitosan derivative, DEAE-CS, is characterized by an increased buffer capacity because it bears tertiary
amino moieties –CH2CH2N(CH2CH3)2. One study that investigated DEAE-CS as a non-viral DNA
delivery carrier showed that it exhibited a comparable transfection efficiency in HeLa cells to that of
the commercial lipid-based transfection agent Lipofectamine [20].
The abundance of quaternized positively charged [–NMe3]+ moieties in the MG-CS backbone
allows it to interact with polyanionic DNA efficiently, thereby protecting bound DNA from enzymatic
degradation by nucleases. However, MG-CS is not a proton-sponge polymer; thus, it is expected to
show only limited ability to escape the endosome. Conversely, the DEAE-CS interacts with DNA to a
lesser degree, but its increased buffer capacity should enhance the endosomal escape of the polyplexes
by the proton-sponge mechanism. Therefore, although both vectors share a similar chemical structure,
each has only one specific advantage: either a high concentration of positively charged moieties in
its backbone (MG-CS) or a high buffer capacity (DEAE-CS). Transfection studies were carried out on
epithelial cells and were extended to include dendritic cells to explore the potential application of these
polymers as DNA vaccines.
2. Materials and Methods
2.1. Materials and Reagents
Crab chitosan with a degree of acetylation (DA) of 0.16 ± 0.02 (determined by 1H NMR
and elemental analysis) and Mw of (8.14 ± 0.16) × 104 g/mol (determined by size exclusion
chromatography coupled to multi-angle light scattering (SEC-MALS)) was purchased from CJSC
Bioprogress (Moscow, Russia). 2-Chloro-N,N-diethylethylamine hydrochloride (DEAE-Cl) and
O-hydroxyethyl-N,N,N-trimethylchitosan iodide (methylglycol-chitosan, MG-CS) were purchased
from Sigma Aldrich (Saint Louis, MO, USA). Dialysis membrane (MWCO 12,000–14,000) was obtained
from Orange Scientific (Braine-l’Alleud, Belgium).
UltraPure™ agarose gel powder was purchased from Invitrogen (Carlsbad, CA, USA). GelRed™
nucleic acid stain (10,000× in water) was obtained from Biotium (Hayward, CA, USA). Gel loading
solution was purchased from Sigma Aldrich and was mixed at a 1:6 ratio with sample before loading.
The 10× UltraPure™ TAE Buffer, consisting of 400 mM Tris-acetate and 10 mM EDTA (pH 8.5,
Invitrogen), was diluted with distilled water to prepare 1× Tris-acetate-EDTA (TAE) electrophoresis
running buffer.
Plasmid DNA (gWiz™ Luciferase, 6732 bp) was purchased from Aldevron (Fargo, ND, USA).
Lipofectamine™ 2000 (henceforth ‘Lipofectamine’) was obtained from Invitrogen and used as the
positive control. The luciferase assay system was purchased from Promega (Madison, WI, USA).
The Bio-Rad Protein Assay Dye Reagent Concentrate (5×) was purchased from Bio-Rad Laboratories
(Hercules, CA, USA). Bovine serum albumin (BSA) was obtained from Sigma Aldrich.
Other chemicals, if not otherwise stated, were obtained from commercial sources and were used
without purification. All solvents were of reagent grade and used as received.
2.2. Synthesis of DEAE-CSI under Heterogeneous Conditions
Chitosan (1.0 g) was mixed with 2 mL of distilled water and 1.5 mL of 35% NaOH solution, and the
mixture was stirred for 2 h using a magnetic stirrer. 2-chloro-N,N-diethylethylamine hydrochloride
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(5.35 g) was dissolved in 21.5 mL of 85% propan-2-ol (IPA: isopropyl alcohol) and added to the alkaline
suspension of chitosan. This reaction mixture was stirred for 3 h at 80 ◦C under a nitrogen flow and
then neutralized with 10% HCl. The DEAE-CSI product was purified by dialysis against distilled
water, tested for an absence of chloride ions, and freeze-dried.
2.3. Synthesis of DEAE-CSII under Homogeneous Conditions
Chitosan (1.0 g) was dissolved in 10 mL of 0.1 M HCl. A solution of 2-chloro-N,N-
dimethylethylamine (5.35 g in 15 mL of distilled water) was then added to the acidic polymer solution,
and the pH was adjusted to 6.5 with sodium acetate. The reaction mixture was stirred at 80 ◦C for 3 h,
followed by addition of 5 mL of 10% HCl. The product was dialyzed against distilled water, tested for
an absence of chloride ions, and freeze-dried.
2.4. Characterization Methods
1H NMR spectra were measured on Bruker Avance II 400 MHz spectrometers (Bruker, Billerica,
MA, USA). Samples were prepared by dissolving 5 mg of polymer in D2O/CF3COOH or D2O/DCl.
Spectra were acquired at 323 or 343 K with suppression of the DOH signal. Integral of the H-1 signals
of the glucosamine moieties of chitosan and its derivatives was used as a reference.
Elemental analysis was performed using a Perkin-Elmer Elemental Analyzer (Perkin-Elmer,
Waltham, MA, USA).
2.5. Size Exclusion Chromatography Coupled to Multi-Angle Light Scattering (SEC-MALS)
Analytical fractionation was performed at room temperature on a system consisting of a PL
Aquagel guard column (Polymer Labs, Amherst, MA, USA), followed by in-series PL Aquagel-OH
60, PL Aquagel-OH 50, and PL Aquagel-OH 40 analytical columns. The samples (100 µL injection
volume; ca. 3.0 mg/mL in acetate buffer) were eluted with acetate buffer (pH 5, 0.2 M) at a flow
rate of 0.7 mL/min (LC-20AD, Shimadzu, Milton Keynes, UK). The eluent was detected online [21]
using multi-angle light scattering (MALS) (Dawn EOS, Wyatt Technology, Santa Barbara, CA, USA)
and differential refractive index (Optilab rEX, Wyatt Technology, Santa Barbara, CA, USA) detectors.
The absolute weight-average molar masses (Mw) and polydispersity indices ( MwMn ) were calculated
using the ASTRA® (Version 5) software (Wyatt Technology, Santa Barbara, CA, USA) and the refractive
index increment, dn/dc = 0.163 mL/g for chitosan and chitosan derivatives [22–24].
2.6. Dynamic Light Scattering (DLS)
A solution of DNA in Dulbecco’s Modified Eagle Medium (DMEM) was mixed with a volume of
chitosan solution determined based on the polysaccharide: DNA mass ratio and then diluted up to
1 mL with DMEM medium to obtain a final DNA concentration of 6.29 µg/mL. The solutions were
vortexed and left to stand for 10 min to allow completion of the complex formation. The sizes of
the complexes were determined with a Zetasizer Nano S90 instrument (Malvern Panalytical, Almelo,
The Netherlands) (scattering angle of 173◦ at 25 ◦C). The average complex size was calculated as a
mean value of three measurements.
2.7. Gel-Retardation Assay
Gel electrophoresis was performed in 1% agarose gel in TAE buffer at a voltage of 120
V using a Bio-Rad Sub-cell GT Basic setup. The intercalating agent was 3,8-diamino-5-ethyl-6-
phenylphenantridium bromide. DNA was detected with a BioRad Molecular Imager ChemiDoc
XRS system (BioRad Laboratories, Hercules, CA, USA).
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2.8. Ethidium Bromide Displacement Assay
An ethidium bromide (EtBr) displacement assay was performed according to Oliveira et al. [20],
with minor modifications. Briefly, 2.5 µL of EtBr solution in water (2.5 × 10−3 M) was added to
2 mL of phosphate buffer saline (PBS, pH 7.4). The DNA stock solution was then added to final
DNA concentration of 5 ng/µL. The solution was then titrated with polysaccharide solution in
PBS (1 mg/mL) from mass ratios of 0.1:1 to 10:1. Measurements were recorded using a Shimadzu
RF-5301PC spectrofluorometer (λex = 560 nm; λem = 605 nm).
2.9. Cell Culture
Calu-3 cells (human lung adenocarcinomic bronchial epithelial cells) and JAWSII cells (mouse
immature dendritic cells) were obtained from American Type Culture Collection (Manassas, VA,
USA). Calu-3 cells were grown in DMEM/F-12 medium supplemented with 10% fetal bovine serum
(FBS) and were cultured once a week; JAWSII cells were cultured in α-minimum essential medium
supplemented with 20% FBS and 5 ng/ml recombinant mouse granulocyte-macrophage colony
stimulating factor (GM-CSF) and were subcultured once weekly. All the cell culture media contained
1% antibiotic/antimycotic liquid, and all cells were maintained at 37 ◦C in a 5% CO2 atmosphere.
2.10. DNA Transfection
Calu-3 cells and JAWSII cells in 24-well plates were transfected with chitosan derivative/DNA
complexes by adding 1 µg luciferase plasmid per well. Lipofectamine was used as a control.
The complexes were prepared at different chitosan to DNA mass ratios in Opti-MEM I reduced
serum medium, with a final volume of 400 µL per well. The cells were transfected when they
had reached 70–80% confluency. After incubating the cells with the complexes for 5 h at 37 ◦C,
the transfection medium was removed and replaced with serum-supplemented cell culture medium.
At 24 h post-transfection, the medium was aspirated, and the cells were lysed in 100 µL Promega
reporter lysis buffer. The plates were then subjected to three freeze-thaw cycles to achieve complete
cell lysis prior to the luminescence detection step. The luciferase expression was detected using the
luciferase assay system according to the manufacturer’s protocol. In brief, 20 µL of cell lysate was
transferred to a black 96-well plate, and the relative light unit (RLU) was detected by a luminometer
(MLX Microtiter® Plate Luminometer, Dynatech Laboratories, Inc. Chantilly, VA, USA) with an
auto-feeding and detection system. The luminometer was programmed to inject 100 µL of reconstituted
luciferase assay substrate per well and to perform a 2 s luminescence measurement (RLU). The results
were expressed as relative light units (RLU) per mg of total protein.
2.11. Bradford Protein Quantification
After transfection, the cell lysates were centrifuged at 12,000× g for 2 min at 4 ◦C.
The concentration of total protein in the cell supernatant was determined by the Bradford method.
The Bradford protein assay reagent (5×) was diluted to a 1× working solution with distilled water and
filtered through filter paper. Bovine serum albumin (BSA), dissolved in distilled water at 1 mg/mL,
was used to prepare a protein standard curve with concentrations ranging from 0.2 to 1 mg/mL.
Sample solutions and protein standards were added to a 96-well plate and mixed with 200 µL 1×
Bradford protein assay reagent for 5 min on a plate shaker at room temperature. The absorbance
of the samples was measured at 595 nm with an Epoch 96-well Microplate Spectrophotometer
(BioTek Instruments Inc., Winooski, VT, USA). Sample protein concentrations were calculated from
the BSA standard curve.
2.12. Assessing the Toxicity In Vitro
The toxicity of the polymers in Madin-Darby canine kidney (MDCK) cells was assessed by
serially diluting the polymer stock solutions in alpha-MEM maintenance medium. These solutions,
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in 6 replicates, were added in amounts of 0.1 mL per well to 96-well plates containing confluent
MDCK cell monolayers (~10,000 cells). After incubation for 24 h at 37 ◦C in a 5% CO2 atmosphere,
a micro tetrazolium assay was performed. The cells were washed twice with phosphate buffered
saline (PBS), and then 0.1 mL of 0.5 µg/mL 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide
(MTT) solution in PBS was added to each well. After a 1 h incubation (37 ◦C and 5% CO2),
the medium was removed and 0.1 mL of 95% C2H5OH was added to each well to dissolve the
(E,Z)-5-(4,5-dimethylthiazol-2)-1,3-diphenyformazan (formazan) crystals. The optical density was
measured at 535 nm using a multifunctional CLARIOstar® reader (BMG LABTECH, Ortenberg,
Germany). The obtained results were used to calculate the LC50 of the chitosan derivatives. The toxicity
of Lipofectamine 2000 was assessed under the same conditions at amounts of 1.25–5 µL per well,
as recommended by the manufacturer’s protocol.
2.13. Statistical Analysis
The data were analyzed using one-way ANOVA followed by a Bonferroni post-hoc test.
The analysis was performed for each derivative independently with q = 3 using naked DNA and
Lipofectamine as controls in transfection and cytotoxicity experiments, respectively. Calculations were
performed using online service astatsa.com.
3. Results and Discussion
3.1. Characterization of MG-CS
Previous studies unambiguously demonstrated a strong dependence of the key characteristics
of chitosan-based gene therapy vectors, such as their transfection efficiency and cytotoxicity, on the
Mw, the degree of acetylation (DA), and the degree of substitution (DS) of the chitosan derivative
used [11]. MG-CS (Figure 1) possesses hydroxyethyl moieties at C-6 and C-3 atoms and quaternized
[–N(CH3)3]+ moieties at the C-2 atom of the pyranose ring. Thus, the Mw and DS (denoted, in the
case of MG-CS, as the degree of glycolization, DG), the DA, and the degree of quaternization (DQ)
are important structural characteristics that influence the transfection and cytotoxic properties of
MG-CS-based vectors.
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The MG-CS used here was obtained from a commercial source and was characterized by 1H NMR
spectroscopy to evaluate its DA, DG and DQ. The NMR spectrum of MG-CS (Figure 1) displayed all
the characteristic signals of the chitosan backbone: 3.5–4.6 (H-2,3,4,5,6), 5.43 (H-1 from GlcN+Me3).
The signals of N-methyl protons were represented by a sharp singlet at 3.34 ppm.






The glycol moiety signals were overlapped by polysaccharide backbone signals, so the DG














indicates a complete quaternization of the chitosan amino groups. All integrals were normalized with
respect to the H-1 signals of the glucosamine moieties of MG-CS. The results are shown in Table 1.
Table 1. Characteristics of the chitosan derivatives.





0.13 114,000 ± 3000 1.36 ± 0.07 30.8 4.95 2.910.87 (DQ)
Chitosan -
0.15
81,400 ± 1600 2.10 ± 0.40 36.6 8.21 6.54(0.17) 3
DEAE-CSI 1.2 0.17 134,000± 1000 1.68 ± 0.08 45.1 7.61 7.51
DEAE-CSII 0.57 0.18 84,500 ± 1700 1.64 ± 0.07 39.8 8.08 7.13
1 Determined by 1H NMR spectroscopy; 2 Determined by SEC-MALS; 3 Determined from elemental analysis data.
3.2. Synthesis and Characterization of DEAE-CS
DEAE-CS was synthesized using two different protocols involving the interaction of DEAE-Cl and
chitosan. The first protocol (Section 2.2) included the reaction between chitosan and DEAE-Cl under
heterogeneous conditions in an alkaline (IPA-NaOH) medium. The second procedure (Section 2.3)
involved treatment of chitosan with DEAE-Cl in acetate buffer solution under homogeneous conditions
at pH 6.5. In both cases, we obtained water-soluble chitosan derivatives (DEAE-CSI and DEAE-CSII,
respectively), which were then characterized by 1H NMR spectroscopy.
The 1H NMR spectrum of DEAE-CSII (Figure 2) shows three signals that provided information
about the degrees of substitution. The triplet at 1.35 ppm corresponds to the methyl group protons
of the CH3–CH2– moiety. N-substitution is confirmed by a shift in the anomeric proton signal to the
weak field (5.1 ppm). The methylene protons of the CH3–CH2– moiety are represented by a strong
signal at 3.33 ppm. These signals are overlapped with the H-2 signal of the glucosamine units. The DS
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The 1H NMR spectrum of the DEAE-CSI synthesized in IPA-NaOH medium (Figure 2) indicates
the generation of highly substituted products. Thus, treatment of chitosan with a fivefold excess of
DEAE-Cl in IPA-NaOH generated DEAE-CS with DS = 1.2, while treatment in acetate buffer solution at
pH 5–6 for the same duration and with the same concentration of reactants and the same temperature
gave a product with DS = 0.57. The anomeric proton shift in DEAE-CSI shows that about 75% of
the amino groups are substituted. Methyl protons of the DEAE substituent are represented by three
superimposed triplets that can be explained by the presence of O- and N-substitution and alkylation of
the tertiary amino group by DEAE-Cl. However, further investigations are required for determination
of the molar fractions of each substituent.
In the case of DEAE-CSII, only one kind of substituent is observed, and this is also confirmed by
the correlation between the integrals of the methyl group and the shifted anomeric proton. Integration
of the acetamide proton (2.08 ppm) shows no occurrence of deacetylation in either the acetate buffer
solution or the IPA-NaOH medium (Table 1).
Thus, DEAE-CS with different DS was synthesized by a convenient and straightforward one-stage
protocol. The reaction between chitosan and DEAE-Cl under homogeneous conditions in acetate
buffer solution leads to the formation of an N-substituted DEAE-CSII with a moderate DS, whereas the
reaction conducted under heterogeneous conditions in IPA-NaOH medium gives rise to a highly
substituted DEAE-CSI.
The SEC-MALS data (Table 1) showed that all the polymers used in our study had comparable
Mw (around 105 g/mol). The Mw of DEAE-CS increased with increases in the DS. The commercial
sample of MG-CS had the lowest polydispersity index (PDI), which was almost half that of chitosan.
By contrast, the synthesis of DEAE-CS decreased the PDI, which may be explained by diffusion of the
low molecular weight fractions through the dialysis membrane.
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substitution of 1.2 and 0.57, respectively) (343 K, 400 MHz, D2O + CF3COOH).
3.3. Assessing the Toxicity In Vitro
The MTT assay showed that all the studied chitosan derivatives exhibited
concentration-dependent cytotoxicity. MG-CS had the lowest toxicity since it decreased cell
viability only to 80% even at the highest concentration studied. The cytotoxicity of DEAE-CS
was determined by its DS. Increasing the DS from 0.57 to 1.2 diminished cell viability from 65%
(for DEAE-CSII) to 10% (for DEAE-CSI) (Figure 3). Note that the highest polysaccharide concentration
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used in transfection experiments was 2.5 µg/mL (at 10:1 ratio). Four times higher polysaccharide
concentration (10 µg/mL) was less harmful in most cases than the lowest studied Lipofectamine
dose (Figure 3). Therefore, all three chitosan derivatives proved to be significantly less cytotoxic
than Lipofectamine. Hence they are considered to be safer and more suitable than Lipofectamine for
therapeutic use.
3.4. Evaluation of DNA Binding Affinity
The DNA binding ability of DEAE-CS and MG-CS was studied by agarose gel electrophoresis.
Polyplexes of MG-CS, DEAE-CSI, and DEAE-CSII were prepared at different polysaccharide:DNA
mass ratios (1:1, 2:1, 5:1, 10:1, 20:1 and 30:1). Figure 4 demonstrates that the DNA migration was
completely retarded at a polysaccharide:DNA mass ratio of 2:1. This can be explained by complete
DNA binding and negative charge neutralization.
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We quantitatively evaluated the process of DNA binding by chitosan derivatives with a fluorescent
intercalator (EtBr) displacement assay. This method is based on the competitive displacement of a
cationic dye by cationic polysaccharides, which results in fluorescence quenching.
As shown in Figure 5a, fluorescence quenching curves can be described by two linear fragments
and a smooth transition between them. At low polysaccharide:DNA mass ratios, the fluorescence
intensity rapidly decreases due to polyplex formation. Around the stoichiometric ratio, a smooth
transition represents a dynamic equilibrium of the polyplex association-dissociation processes,
whereas an excessive polysaccharide amount results in a slow linear decrease due to nonspecific
fluorescence quenching.
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The rel tive fluorescence intensity (Q, %) and the fraction of bound DNA (B, %) were calculated
using the following formulas:
Q =
Fx − FEB
F0 − FEB × 100, B =
100−Q
100− (aR + b) × 100, (5)
where Fx, F0, and FEB are the fluorescence intensities at x equivalents of polysaccharide
added, before titration, and for the blank EtBr solution, respectively; R is the polysaccharide:DNA
mass ratio; a and b are empirical constants of post-saturation curve fragment linear fitting.
The intersection of the linear curve fragments provides information about the stoichiometric
polyplex composition. This was 1.1:1 for both MG-CS and DEAE-CSI 1.2:1 for DEAE-CSII. As shown in
Figure 5b, at a mass ratio higher than 2:1, more than 95% of the DNA is bound in polyplexes. This fact
corresponds well with the gel retardation assay data.
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3.5. DLS Measurements
Several previous studies have shown that the penetration of polyplexes through cell membranes
strongly depends on their size. The optimal size for transfection is generally accepted as about 200 nm
or less [25–27]. In the present study, the dependence of polyplex size on polymer composition was
studied using DLS.
Polyplexes based on three derivatives (DEAE-CSI, DEAE-CSII, and MG-CS) were prepared at five
different polysaccharide:DNA mass ratios of 1:1, 2:1, 5:1, 10:1, and 20:1. All polyplexes revealed similar
patterns of hydrodynamic diameter (2Rh), which changed at different ratios. At some ratios, the size
increase ceases and is followed by a gradual decline (Figure 6). The effect of these size decreases can
be explained by a more effective nucleic acid binding and by electrostatic repulsive forces that prevent
aggregation among the complexes.
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3.6. In Vitro DNA Transfection Efficiency
The in vitro transfection was performed in Calu-3 and JAWSII cells. Polyplexes based on
DEAE-CSI, DEAE-CSII, and MG-CS were formulated at different polysaccharide:DNA ratios
(2:1, 5:1, and 10:1) and compared to Lipofectamine:DNA complexes (ratio 2:1). The transfection
efficiency in Calu-3 cells was lower for both the DEAE-CS and MG-CS derivatives than for
Lipofectamine. The highest transfection efficiencies were obtained from chitosan-based particles
with a 10:1 mass ratio, which is in line with our DLS data showing that, at the 10:1 ratio, all derivatives
form complexes with sizes close to 200 nm (Figure 7a). In general, higher transfection efficiency was
achieved when the polyplexes were prepared at higher polysaccharide:DNA ratios, possibly due to
the formation of smaller polyplexes that facilitated cellular uptake and presence of free cationic chains
promoting the endosomal escape.
As expected, a slightly better efficiency was achieved in transfection experiments with DEAE-CSI
(with a higher DS) than with DEAE-CSII. Moreover, within the same DS, the transfection efficiency of
DEAE-CS derivatives was poorly correlated with the mass ratio. However, in the case of MG-CS:DNA
complexes, the mass ratio had a marked effect on transfection, as the effectiveness of MG-CS improved
with an increase in the polysaccharide:DNA ratio. Figure 7a shows that the difference in the transfection
efficiency of DEAE-CSI and MG-CS at a polysaccharide:DNA ratio = 2:1 was not statistically significant.
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In general, transfection was poorer in JAWSII cells than in Calu-3, HeLa, and many other cell
lines [28,29]. In this context, a comparison of the transfection activity of DEAE-CS and MG-CS vectors
versus Lipofectamine into JAWSII cells was of interest. The results of these experiments are presented
in Figure 7b. The transfection efficiency of DEAE-CSI, DEAE-CSII, and MG-CS at polysaccharide:DNA
ratios of 5:1 and 10:1 showed no statistically significant difference. However, the expression level of
luciferase was higher for DEAE-CSI at a polysaccharide:DNA ratio of 2:1 than for DEAE-CSII and
MG-CS polyplexes formulated at the same ratio. In general, the efficacy of Lipofectamine and MG-CS
decreased in experiments with JAWSII cells when compared to experiments conducted using the
Calu-3 cells, whereas the efficiency of DEAE-CS remained close to that determined in the previous
Calu-3 experiment.
4. Conclusions
The following conclusions can be drawn from the results of this work:
1. The interaction of DEAE-Cl with chitosan at pH 5–6 furnishes N-substituted DEAE-CSII with
a moderate DS, whereas the reaction in alkaline medium leads to a highly substituted product
with a more uncertain pattern of substitution.
2. Both DEAE-CS and MG-CS efficiently bind DNA to form stable self-assembled polyplexes at
polysaccharide:DNA ratios greater than 2:1. The stoichiometry of the polyplexes was about 1:1.
3. In Calu-3 cells, the DNA transfection activity of MG-CS improves with increasing
polysaccharide:DNA ratios. By contrast, the transfection efficiency of DEAE-CS is lower and
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has no expressed dependency on the DS or the polysaccharide:DNA ratio. In JAWSII cells,
both Lipofectamine and MG-CS show significantly less DNA transfection activity, while the
efficiency of DEAE-CS remains at the same level as seen in Calu-3 experiments (or even
slightly increases).
4. The toxicity of DEAE-CS rises with increasing concentrations of the polymer and its DS, whereas
MG-CS demonstrates only moderate cell toxicity, even at the highest concentration studied.
Overall, MG-CS proved to be a more efficient and significantly less toxic vector when compared
to DEAE-CS. However, DEAE-CS is also of interest for two reasons: it does not lose its effectiveness
in the transfection-recalcitrant JAWSII line, and the synthesis of this polymer is a one-stage and
straightforward reaction. By contrast, MG-CS must be synthesized in several stages, including
protection-deprotection, and some of these steps proceed under harsh conditions. Taken together,
the results from in vitro experiments confirmed that both DEAE-CS and MG-CS are promising
natural-based gene delivery vectors that need further study, especially in in vivo conditions.
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Appendix A
Table A1. Statistical analysis of the transfection experiments.
Pair vs. Naked DNA
Calu-3 Cells JAWSII Cells
Bonferroni p-Value Significance Bonferroni p-Value Significance
MG-CS
2:1 1 0.85 ns 2.8 ns
5:1 0.005 ** 0.22 ns
10:1 5 × 10−5 ** 0.026 *
DEAE-CSI
2:1 0.025 * 1.8 ns
5:1 0.002 ** 0.14 ns
10:1 0.005 ** 0.28 ns
DEAE-CSII
2:1 0.21 ns 2.1 ns
5:1 0.061 ns 0.14 ns
10:1 0.025 * 0.025 *
1 Polysaccharide: DNA mass ratio; * p < 0.05; ** p < 0.01; ns p > 0.05.
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